Testing follow-up chemo and radiation for high-risk breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies a standard follow-up treatment plan that combines chemotherapy and radiation after surgery, and it looks for blood/tissue “biomarkers” that predict who benefits most. If you have high-risk breast cancer that didn’t fully disappear after initial (neoadjuvant) chemo, you may be eligible to help guide better future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent and follow study visits
- You have stage I to IIIB breast cancer and have already had chemo, then surgery (lumpectomy or mastectomy)
- After surgery, there is still leftover cancer at a certain minimum level
- You plan to start radiation within 12 weeks after your last cancer surgery
- Your general health is fairly good (ECOG 0–2) and your blood counts and organs meet lab cutoffs
- You can take the study treatment safely (including heart-function limits if T-DM1 is used) and you are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatments for early breast cancer (stage II or III). It aims to find better therapies that can stop the cancer from coming back, and you may receive a promising new drug.
This study tests a combination of an immunotherapy drug (toripalimab) and a targeted type of radiation called SBRT for breast cancer that didn't shrink with standard chemo. It aims to see if this combination can help your body fight the cancer better.
This Phase 3 study tests a specific plan that combines chemotherapy (and sometimes targeted medicines) with radiation before surgery for one breast. It may help shrink breast cancer and improve treatment timing, based on how well tumors respond.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This Phase 4 study tests an additional (adjuvant) treatment for breast cancer after surgery and standard follow-up care. It may help lower the chance the cancer comes back, but you must match specific tumor and body-chemistry requirements to join.
This trial tests a combination of chemotherapy, an immunotherapy drug, and two different schedules of radiation before surgery for a common type of breast cancer. The goal is to find which radiation approach works better and to improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.